Gonablok 50 Capsule contains Danazol 50 mg, a synthetic steroid derivative with anti-gonadotropic and weak androgenic properties. It is primarily indicated for the management of endometriosis, fibrocystic breast disease, and hereditary angioedema. Danazol exerts its therapeutic effects by inhibiting the mid-cycle surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), thereby suppressing ovarian steroidogenesis and reducing estrogen production. This hormonal modulation leads to the regression of ectopic endometrial tissue and alleviation of associated symptoms such as pelvic pain and dysmenorrhea. Additionally, Danazol stabilizes vascular permeability in hereditary angioedema, reducing the frequency and severity of angioedema attacks. Gonablok 50 Capsule is administered orally, with dosage and duration tailored to the specific condition and patient response. Common adverse effects include weight gain, acne, hirsutism, voice changes, and menstrual irregularities, attributed to its androgenic activity. It is contraindicated in pregnancy, lactation, hepatic dysfunction, and androgen-dependent tumors. Regular monitoring of liver function tests and lipid profiles is recommended during therapy. Gonablok 50 Capsule should be prescribed and used under strict medical supervision to ensure efficacy and minimize potential risks.